Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to -$430134.0.

  • Dare Bioscience's Cash from Operations rose 9273.92% to -$430134.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year increase of 2388.51%. This contributed to the annual value of $5.4 million for FY2024, which is 11389.72% up from last year.
  • Per Dare Bioscience's latest filing, its Cash from Operations stood at -$430134.0 for Q3 2025, which was up 9273.92% from -$5.4 million recorded in Q2 2025.
  • In the past 5 years, Dare Bioscience's Cash from Operations registered a high of $12.9 million during Q2 2024, and its lowest value of -$16.1 million during Q1 2023.
  • In the last 5 years, Dare Bioscience's Cash from Operations had a median value of -$6.6 million in 2023 and averaged -$4.8 million.
  • As far as peak fluctuations go, Dare Bioscience's Cash from Operations surged by 55136.92% in 2022, and later tumbled by 19271.65% in 2023.
  • Over the past 5 years, Dare Bioscience's Cash from Operations (Quarter) stood at -$9.9 million in 2021, then soared by 40.53% to -$5.9 million in 2022, then plummeted by 38.7% to -$8.2 million in 2023, then soared by 163.97% to $5.2 million in 2024, then tumbled by 108.22% to -$430134.0 in 2025.
  • Its last three reported values are -$430134.0 in Q3 2025, -$5.4 million for Q2 2025, and -$5.5 million during Q1 2025.